Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples